All drug use has associated risk, and interventions that prevent drug-related deaths and blood-borne viruses can keep people safe as they recover. Local recovery-orientated treatment systems, which cater for those at risk of drug-related death and contracting blood-borne viruses, will be recognised by:
All services which are part of a recovery-orientated system will be able to deliver some level of these, with some more appropriately placed to deliver certain interventions.
Trends in drug misuse deaths in England, 1999-2014 [PHE, 2016] PDF (757kb)
PHE’s updated analysis of trends in drug misuse deaths in England. The report also shows the results of matching data on drug misuse deaths to drug treatment data to explore the timing of drug misuse deaths in relation to treatment.
Drug alerts and local drug information systems [PHE, 2016]
Advice to help local authorities assess intelligence received about new, potent, adulterated or contaminated drugs and, if appropriate, issue public health alerts.
Drug alerts and local drug information systems Appendix 4 – LDIS form [PHE, 2016]
A template form for reporting local drug intelligence as local system.
Drug alerts and local drug information systems Appendix 6 – grading and efficacy matrices [PHE, 2016]
Template matrices for grading local drug intelligence and assessing whether to issue a local alert.
In addition to the guidance and evidence listed here, the Alcohol Learning Centre is a well developed resource. For more information see the Topics and Resources page.
PHE’s analysis of trends in drug misuse deaths in England. The report also shows the results of matching data on drug misuse deaths to drug treatment data to explore the timing of drug misuse deaths in relation to treatment.
A slide pack for PHE centres and local areas on the supply of take-home naloxone following new legislation on 1 October 2015. It supplements earlier PHE naloxone advice (http://www.nta.nhs.uk/uploads/phetake-homenaloxoneforopioidoverdosefeb2015rev.pdf)
This briefing provides an overview of the key issues that local providers and commissioners of drug and hepatitis treatment should consider.
This briefing aims to support local authorities and drug treatment and healthcare services to review their BBV prevention and treatment interventions for people who inject drugs. It is the eighth in a series to support improvements in the recovery orientation of services as recommended by ‘Medications in recovery: re-orientating drug dependence treatment’, the final report of the John Strang-chaired Recovery Orientated Drug Treatment expert group.
The fifth in a series of briefings to support commissioners and providers who want to improve the recovery orientation of their services as recommended by ‘Medications in recovery: re-orientating drug dependence treatment’, the final report of the John Strang-chaired Recovery Orientated Drug Treatment expert group.
Provides commissioners of drug treatment services, and commissioners of infectious disease identification and treatment services, with information on best practice around commissioning of hepatitis C services for people who inject drugs.
Evidence-based practice advice on the care of children, young people and adults with chronic hepatitis B.
Sets out what high-quality care should include. Contains specific quality statements directly relevant to this outcome, which can be accessed, along with further information, by following the link.
Provides comprehensive guidance for the UK drug treatment workforce on drug misuse treatment, including evidence-based measures to prevent drug-related deaths and blood-borne virus transmission. These include guidance on blood-borne virus testing, diagnosis and treatment, overdose prevention and training, and access to needle and syringe programmes.
Needle and syringe programmes (NSPs) are vital in preventing the spread of blood-borne viruses. This is NICE’s formal guidance for optimal NSP provision. The six recommendations relate to over-18 injectors of illicit substances and non-prescribed anabolic steroids. It will help local areas provide appropriate public health services for injectors.
Reviewing the causes of drug-related deaths can make a vital contribution to preventing future deaths. This document contains ideas and examples of local practice in reviewing drug-related deaths. It is for people who commission and plan local strategic responses to drug misuse, including service providers.
Blood-borne virus surveillance is key for understanding the level and type of response needed for injectors at risk. The annual survey measures injectors’ blood-borne virus prevalence, and risk and protective behaviours. The data are used to develop preventative and health education campaigns, evaluate their impact, and assist in service provision.
Naloxone can be part of local responses to prevent drug-related deaths. The NTA naloxone programme found that naloxone provision is beneficial for carers and service users, and may prevent drug-related deaths. The report describes the evaluation findings, including the benefits of, and challenges in local naloxone provision.
Understanding trends in drug-related deaths is important, for determining the type and level of response to prevent future deaths. This annual report presents official statistics for England and Wales on deaths related to drug poisoning and drug misuse, by cause of death, sex, age and substance(s) involved.
Drug injectors are at risk of contracting hepatitis C. The HPA’s annual reports provide current surveillance data and evidence on hepatitis C incidence and prevalence, access to treatment, and recommendations for prevention, diagnosis and treatment.
Contains good practice for prevention and control of infectious diseases among injectors. It identifies seven key intervention components that should be applied and, if possible, combined to achieve the maximum prevention effect through synergy. It relates directly to the outcome of preventing the spread of blood-borne viruses.
Highlights good practice in preventing drug related deaths and blood borne viruses based on the results of a 2006-7 NTA/Healthcare Commission service review.